Longidaza
Phase 3Small molecule
Longidaza is one of 11 small molecule programs targeting Bacterial Vaginosis. It is currently in Phase 3.
1
Indications
2
Total Trials
1
Active Trials
10
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
16 competitors in Bacterial Vaginosis
#DrugCompanyPhaseTrials
1Flagyl
DDePuy Orthopaedics
Approved
Acanya
PfizerApproved
Decadron
AAspen Global Incorporated
Approved
Amoxil
GGlobal Antibiotics Research and Development Partnership
Approved
Mycostatin
GGood Molecules, LLC
Approved
Lotrimin
BayerPhase 3
Rocephin
CConrado Roberto Hoffmann Filho
Phase 3
Zithromax
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Phase 3
Doxycyclin
TTanta University
Phase 3
Metronidazole Suppositories
PPeking University Shenzhen Hospital
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Longidaza. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- NNPO Petrovax